Glucoris M2 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake in muscle tissues. The prolonged-release formulation of Glucoris M2 Forte ensures a sustained therapeutic effect, improving glycemic control while minimizing fluctuations in plasma drug concentrations. This combination is particularly beneficial for patients inadequately controlled on monotherapy or lifestyle modifications alone. It aids in achieving optimal glycemic targets, reducing the risk of diabetes-related complications such as neuropathy, retinopathy, and cardiovascular events. Glucoris M2 Forte should be administered under medical supervision with regular monitoring of blood glucose, renal function, and potential adverse effects including hypoglycemia, gastrointestinal disturbances, and lactic acidosis. Dose adjustments may be necessary based on clinical response and tolerability. This medication is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Glucoris M2 Forte Tablet PR represents an effective therapeutic option for comprehensive glycemic management in type 2 diabetes mellitus.